查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598726

溃疡性大肠炎市场：依药物、疾病、给药途径- 全球预测 2025-2030

Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年溃疡性大肠炎市值为74.5亿美元，预计2024年将达到81.4亿美元，复合年增长率为9.41%，到2030年将达到139.9亿美元。

溃疡性大肠炎（UC）是一种慢性发炎性肠道发炎性肠道疾病，主要涉及结肠最内部的发炎。 UC 对医疗保健市场的影响是巨大的，其盛行率不断上升，需要有效的治疗和管理策略。由于饮食变化、压力、遗传和环境触发因素等因素，UC 的盛行率不断增加，因此需要解决 UC 问题。因此，随着诊断和管理医疗设备的进步，对新型治疗剂（包括生物製药、生物相似药和小分子）的需求不断增加。最终使用领域包括主要关注胃肠道疾病的医院、诊所和研究机构，旨在改善患者的治疗结果和生活品质。影响该市场成长的关键因素包括人口老化、诊断方法的改进和产品创新。个人化医疗和标靶治疗的最新趋势，以免疫疗法和基因编辑技术的突破为突出，有可能提高治疗效果和患者依从性，带来了巨大的商机。儘管有这些前景光明的趋势，但市场仍面临一些限制，例如治疗成本高、新兴经济体的认识有限以及严格的监管核准程序可能会抑制新开发和商业化。此外，有关副作用和抗药性的持续挑战需要持续的研究和创新。完美的创新领域包括非侵入性诊断工具的开发、生技药品和生物相似药的进步，以及人工智慧在病患监测和药物开发中的整合。业务成长机会包括建立药物开发策略伙伴关係、研究和培养精准健康解决方案以及投资于患者教育计划。 UC 市场的本质是动态且快速发展的，受到技术进步和对以患者为中心的护理日益关注的推动，因此相关人员需要具有适应性和主动性，以发现新的机会，并保持这一市场极为重要。

主要市场统计
基准年[2023] 74.5亿美元
预测年份 [2024] 81.4亿美元
预测年份 [2030] 139.9亿美元
复合年增长率（%） 9.41%

市场动态：快速发展的溃疡性大肠炎市场的关键市场洞察

供需的动态交互作用正在改变溃疡性大肠炎市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球溃疡性大肠炎发生率上升
    • 改善医疗设施并发展药物开发部门
    • 病患援助计划和报销政策的可用性
  • 市场限制因素
    • 原料成本波动
  • 市场机会
    • 持续研发新药製造
    • 公共和私营部门更多参与生技药品研究
  • 市场挑战
    • 政府对生物相似药核准的严格规定

波特五力：开拓溃疡性大肠炎市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解溃疡性大肠炎市场的外部影响

外部宏观环境因素在塑造溃疡性大肠炎市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解溃疡性大肠炎市场的竞争格局

溃疡性大肠炎市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵溃疡性大肠炎市场供应商的绩效评估

FPNV定位矩阵是评估溃疡性大肠炎市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了溃疡性大肠炎市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对溃疡性大肠炎市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球溃疡性大肠炎的发生率正在上升
      • 加强医疗保健设施并发展药物开发部门
      • 病患援助计划和报销政策的可用性
    • 抑制因素
      • 原料成本波动
    • 机会
      • 新药生产持续研发
      • 公共和私人组织更多参与生技药品研究
    • 任务
      • 政府对生物相似药的核准有严格的规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章溃疡性大肠炎药物市场

  • 发炎药
  • 抗TNF生物製药
  • Calcineurin抑制剂
  • 免疫抑制剂

第七章溃疡性大肠炎市场：依疾病分类

  • 暴发性结肠炎
  • 左侧结肠炎
  • 全结肠炎或全身性结肠炎
  • 直肠乙状结肠炎
  • 溃疡性直肠炎

第八章溃疡性大肠炎市场：依给药途径

  • 可注射的
  • 口服

第九章北美和南美溃疡性大肠炎市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区溃疡性大肠炎市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲溃疡性大肠炎市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-0335FFDBEF39

The Ulcerative Colitis Market was valued at USD 7.45 billion in 2023, expected to reach USD 8.14 billion in 2024, and is projected to grow at a CAGR of 9.41%, to USD 13.99 billion by 2030.

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease that primarily involves inflammation of the colon's innermost lining. Its impact on the healthcare market is substantial, with a growing prevalence that necessitates effective treatments and management strategies. The necessity of addressing UC lies in its increasing prevalence, driven by factors such as changing dietary habits, stress, genetics, and environmental triggers. This has intensified the demand for novel therapeutics, including biologics, biosimilars, and small molecules, alongside advancements in medical devices for diagnostics and management. Application and end-use sectors primarily include hospitals, clinics, and research institutes focusing on gastrointestinal diseases, aiming to enhance patient outcomes and quality of life. Key factors influencing growth in this market include an aging population, better diagnostic methods, and incremental product innovations. Recent developments in personalized medicine and targeted therapies offer substantial opportunities, underscored by revolutionary breakthroughs in immunotherapies and gene editing technologies which can potentially improve treatment efficacy and patient adherence. Despite these promising trends, the market faces limitations such as high treatment costs, limited awareness in emerging economies, and stringent regulatory approval processes that can stifle new development and commercialization. Furthermore, ongoing challenges with side effects and drug resistance necessitate continuous research and innovation. The best areas for innovation include the development of non-invasive diagnostic tools, advancements in biologics and biosimilars, and the integration of AI in patient monitoring and drug development. Prospects of business growth lie in forging strategic partnerships for drug development, cultivating research in precision health solutions, and investing in patient education initiatives. The nature of the UC market is dynamic and rapidly evolving, driven by technological advancements and a growing emphasis on patient-centric care, making it crucial for stakeholders to remain adaptive and proactive in identifying emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 7.45 billion
Estimated Year [2024] USD 8.14 billion
Forecast Year [2030] USD 13.99 billion
CAGR (%) 9.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ulcerative Colitis Market

The Ulcerative Colitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of ulcerative colitis globally
    • Robust availability of healthcare facilities and evolving drug development sector
    • Availability of patient assistance programs and reimbursement policies
  • Market Restraints
    • Fluctuating cost of raw materials
  • Market Opportunities
    • Ongoing research and development in the production of novel drugs
    • Increasing public and private organization involvement in research of biologics
  • Market Challenges
    • Strict government mandates in approval of biosimilars

Porter's Five Forces: A Strategic Tool for Navigating the Ulcerative Colitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ulcerative Colitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ulcerative Colitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ulcerative Colitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ulcerative Colitis Market

A detailed market share analysis in the Ulcerative Colitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ulcerative Colitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ulcerative Colitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ulcerative Colitis Market

A strategic analysis of the Ulcerative Colitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ulcerative Colitis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Ulcerative Colitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors, and Immunosuppressant.
  • Based on Disease, market is studied across Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis, Proctosigmoiditis, and Ulcerative Proctitis.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of ulcerative colitis globally
      • 5.1.1.2. Robust availability of healthcare facilities and evolving drug development sector
      • 5.1.1.3. Availability of patient assistance programs and reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of raw materials
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development in the production of novel drugs
      • 5.1.3.2. Increasing public and private organization involvement in research of biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government mandates in approval of biosimilars
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ulcerative Colitis Market, by Drug

  • 6.1. Introduction
  • 6.2. Anti-Inflammatory Drugs
  • 6.3. Anti-TNF Biologics
  • 6.4. Calcineurin Inhibitors
  • 6.5. Immunosuppressant

7. Ulcerative Colitis Market, by Disease

  • 7.1. Introduction
  • 7.2. Fulminant Colitis
  • 7.3. Left-Sided Colitis
  • 7.4. Pancolitis or Universal Colitis
  • 7.5. Proctosigmoiditis
  • 7.6. Ulcerative Proctitis

8. Ulcerative Colitis Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Americas Ulcerative Colitis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Ulcerative Colitis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Ulcerative Colitis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. BioLineRx Ltd
  • 6. Boehringer Ingelheim GmbH
  • 7. Celgene Corporation
  • 8. Circle33, LLC
  • 9. Cosmo Pharmaceuticals NV
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline Plc
  • 12. Johnson & Johnson Services, Inc.
  • 13. Merck & Co., Inc.
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Pfizer Inc.
  • 16. Sanofi SA

LIST OF FIGURES

  • FIGURE 1. ULCERATIVE COLITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ULCERATIVE COLITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ULCERATIVE COLITIS MARKET DYNAMICS
  • TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023